Yashoda Super Specialty Kaushambi
The Subject Expert Committee of Drugs Controller General of India (DCGI) on Wednesday recommended Serum Institute’s indigenously developed quadrivalent human papillomavirus (qHPV) vaccine for cervical cancer patients.
“An expert panel of India’s central drug authority on Wednesday recommended granting of market authorisation to Serum Institute of India (SII) indigenously-developed India’s first Quadrivalent Human Papillomavirus vaccine (qHPV) against cervical cancer”, said a source.
The vaccine has been recommended for cervical cancer patients those above 9 years to 26 years of age for both male and female.According to the source, an application has also been sent to the National Technical Advisory Group on Immunisation (NTAGI).
The NTAGI may take the final decision on the HPV vaccine in the next meeting scheduled to be held on June 29.
Nearly 294 million people are living with hypertension in the Southeast Asia Region. Over 24…
The World Health Organization (WHO) on Saturday released the updated Bacterial Priority Pathogens List (BPPL)…
The All India Institute of Medical Sciences (AIIMS) has signed a Memorandum of Understanding (MoU)…
As many as one-third of all urban children in India aged 5-15 years are expected…
The Supreme court has reserved its order on a contempt plea against Baba Ramdev, Acharya…
Although nutrition and health claims are regulated by FSSAI, consumers are advised to exercise caution…